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Background: Animal studies have shown that methylphenidate (MPH) and fluoxetine (FLX) have different effects
on dopaminergic and serotonergic system in the developing brain compared to the developed brain. The effects of
Psychotropic drugs On the Developing brain (ePOD) study is a combination of different approaches to determine
whether there are related findings in humans.
Methods/Design: Animal studies were carried out to investigate age-related effects of psychotropic drugs and to
validate new neuroimaging techniques. In addition, we set up two double-blind placebo controlled clinical trials
with MPH in 50 boys (10–12 years) and 50 young men (23–40 years) suffering from ADHD (ePOD-MPH) and with
FLX in 40 girls (12–14 years) and 40 young women (23–40 years) suffering from depression and anxiety disorders
(ePOD-SSRI). Trial registration numbers are: Nederlands Trial Register NTR3103 and NTR2111. A cross-sectional cohort
study on age-related effects of these psychotropic medications in patients who have been treated previously with MPH
or FLX (ePOD-Pharmo) is also ongoing. The effects of psychotropic drugs on the developing brain are studied using
neuroimaging techniques together with neuropsychological and psychiatric assessments of cognition, behavior and
emotion. All assessments take place before, during (only in case of MPH) and after chronic treatment.
Discussion: The combined results of these approaches will provide new insight into the modulating effect of MPH and
FLX on brain development.
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The brain in development is dependent on the emergence
of critical developmental processes (i.e. synaptogenesis,
[1], and therefore sensitive to pharmacological interven-
tions. Treating children and adolescents with serotonergic
(5-HTergic) or dopaminergic (DAergic) drugs like fluoxet-
ine (FLX) and methylphenidate (MPH), is therefore likely
to have influence on the maturation of the brain.
For the 5-HTergic system, FLX (a selective serotonin re-
uptake inhibitor (SSRI), registered for the treatment of de-
pression in children aged 8 years and older, is known to* Correspondence: L.Reneman@amc.uva.nl
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reproduction in any medium, provided the orincrease extracellular levels of 5-HT by blocking the sero-
tonin transporter (SERT). However, animal studies have
demonstrated that periadolescent 5-HT pharmacological
manipulations can lead to abnormal outgrowth of the 5-
HT system [2,3]. Experiments by our group have shown
that chronic treatment with FLX results in a significant in-
crease in prefrontal and hypothalamic 5-HT transporter
(SERT; +30%, p < 0.01) in juvenile-treated rats, but not in
adult treated rats [4]. These findings are in accordance
with Wegerer and Bock who have also shown that this ef-
fect persists into adulthood, long after discontinuation of
treatment with SSRIs [5,6]. Recently it was confirmed that
FLX administration upregulates SERT long-lastingly, also
in non-human primates [7]. These preclinical studies sug-
gest that 5-HT manipulations have an impact on the regu-
lation of 5-HT outgrowth which is dependent on the age
of exposure.l Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
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MPH, a DA reuptake inhibitor and stimulant drug fre-
quently prescribed in the treatment of attention deficit
hyperactivity disorder (ADHD), have demonstrated that
these effects are also age-dependent. For instance, early
treatment with MPH led to a considerable (−50%) reduc-
tion of dopamine transport density (DAT) in rat striatum
when compared to non-treated animals, whereas no ef-
fects were observed in adult animals [8]. These alterations
in the DA system have been shown to result in behavioral
abnormalities. For example, young rats treated with MPH
show more anxiety- and depression-related behavior in
adulthood than adult rats treated with MPH [9].
There is some clinical evidence for related findings in
humans. For example, after concerns about increased sui-
cide risk among children and adolescents treated with
SSRIs, the Food and Drug Administration and European
Medicines Agency (EMEA) stated in 2003–2004 that SSRIs
were contraindicated for treating depression in children
and adolescents. Furthermore, in the NIMH Collaborative
Multisite Multimodal Treatment Study of Children With
Attention-Deficit/Hyperactivity Disorder (MTA) children
who received behavioral therapy had a lower rate of diagno-
ses of anxiety or depression (4.3%) than the children who
were treated with MPH (19.1%) thus indicating a (transient)
increase in the occurrence of emotional disorders six to
eight years after treatment with MPH [10]. Age-related dif-
ferences have also been found between adolescent and
adult patients on fMRI studies, with adolescent patients
treated with MPH showing more activity in the prefrontal
cortex after treatment than adult patients [11].
Thus, evidence is slowly emerging that the long-term ef-
fects of drug exposure are delayed and come to expression
once the vulnerable system reaches maturation (i.e., typic-
ally during adulthood). This phenomenon is known as
‘neuronal imprinting’ and occurs when the effects of drug
exposure outlast the drug itself [12]. Still, very little is
known on exposure during later brain development. Most
(clinical) studies are hampered by the fact that they are
retrospective in design, and therefore the findings could be
caused by other factors on which the groups differed. As
pointed out by Shaw and colleagues: ‘….the ideal study de-
sign for this question would be a randomized trial compar-
ing cortical growth in children on psychostimulants against
an unmedicated comparison group—but this would be
both logistically and ethically challenging’ [13]. Notwith-
standing this challenge, we have set up three studies (the ef-
fects of Psychotropic drugs On the Developing brain
‘ePOD’ project): two randomized controlled trials (RCTs)
and a retrospective cohort study, investigating the possibil-
ity of the existence of neuronal imprinting in children med-
icated with these drugs while using several modalities to
assess neurocognitive development. Here we report on the
objectives and methods of these studies.Objectives
Primary objectives
1. The primary objective of the ePOD studies is to
report on the short-term age-dependency of the effect
(s) of MPH treatment on the developing DA system
and on the age-dependency of the effect(s) of FLX on
the developing 5-HTergic system, using pharmaco-
logical MRI (phMRI) as our main outcome measure.
2. Furthermore, we aim to study the long-term effects
of these drugs in a cohort study based on medical
prescription data.
Secondary objectives
Our secondary objectives are:
1. To report on the age-dependency of MPH and FLX
on the outgrowth of the DA system and the 5-HT
system using functional outcome measures (diffusion
tensor imaging [DTI], functional MRI [fMRI],
restingstate-fMRI [rs-fMRI] and neuropsychological
assessment (NPA)).
2. To report on the age-dependency of the effects of
FLX on 5-HT driven HPA axis activity using cortisol
measures.
3. To report on the role of the 5-HTTLPR polymorph-
ism upon the age-dependency of FLX on the out-
growth of the 5-HT-ergic system.
4. To report on the effects of MPH on restless legs
(RLS) symptoms and insomnia.
Methods/Design
General design of the ePOD project
Only a long-term prospective study in patients randomly
assigned to MPH or SSRIs and placebo conditions can de-
termine unequivocally whether the (adverse) effects of
these medications on the neurotransmitter systems inter-
act with the age when these drugs are prescribed. To this
purpose we designed two RCTs, one with MPH and one
with FLX. However, it would not be ethical to deprive sub-
jects in a placebo setting from treatment for extensive pe-
riods of time. Therefore, in addition to the RCTs, which
will last 4 months, we investigate the long-term effects (at
least 7 years) in a cohort study based on medical prescrip-
tion (the ePOD-Pharmo study). The three sub-studies of
the ePOD project include:
 ePOD-MPH: A 16 week RCT with MPH in 100
medication naïve ADHD patients. This RCT involves
three separate NPA and MRI assessments: the first
before starting with the study medication (baseline
session), the second during treatment with MPH or
placebo (week 8) and the final assessment after trial
end following a 1-week washout period (week 17).
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medication naïve patients suffering from MDD and
anxiety disorders (AD). It involves two seperate NPA
and MRI assessments: before starting with the study
medication (baseline session) and after treatment with
FLX following a 3-week washout period (week 19).
 ePOD-Pharmo: A cohort study based on medical
prescription data. One hundred and fifty subjects
will be recruited through a database containing
prescription data on MPH or FLX (and other
antidepressants) Subjects in this cohort based study
will receive the same assessments as in the RCTs
but only once.
Randomized controlled trials: design and study samples
The two RCTs consist of 16-week multicenter random-
ized, double blind, placebo-controlled trials with a wash-
out period of one week (MPH) or three weeks (FLX).
Subjects are stratified into two age categories: MPH:
boys aged 10–12 years, and adults aged 23–40 years.
FLX: girls aged 12–14 years and adults aged 23–40 years.
These two age groups are randomly assigned to either
placebo or active treatment. MRI and NPA assessments
will take place before treatment (baseline), during treat-
ment (only in the MPH trial) and following the washout
period (see Figure 1 for the timeline for ePOD-SSRI
RCT). Baseline measurements will be compared with the
results obtained at trial end, and for the ePOD-MPH
RCT also during the trial. Differences in outcome mea-
sures will be compared between the two age categories
(children vs. adult), in addition to healthy controls (sep-
arate study). In view of our hypothesis that the active
treatment results in long lasting or even permanent
changes in the developing brain, we expect no or a small
change in change scores between baseline-, and post-
treatment assessments, whereas in children we expect to
find larger changes, as enduring changes will have taken
place in the developing brain, but only transient accom-
modation in the developed brain. Washout periods wereFigure 1 Timeline study procedures SSRI trial; *only in adolescents.chosen based on chemical properties (rate of elimination
based on five half–live times) and ethical considerations
(time without treatment).
A total of 50 children (10–12 years of age) and 50 adult
(23–40 years of age) male outpatients diagnosed with
ADHD (all subtypes) and in need of pharmacological ther-
apy will be included in ePOD-MPH RCT. A total of 40
adolescent (12–14 years of age) and 40 adult (23–40 years
of age) female outpatients with moderate to severe MDD
or an anxiety disorder in need of pharmacological treat-
ment will be included in ePOD-SSRI RCT. Patients that
have used medications or drugs that influence the
monoamine systems before age 23 are not eligible.
Patients are recruited from clinical programs at the Child
and Adolescent Psychiatry Center Triversum (Alkmaar),
from the department of (Child and Adolescent) Psychiatry
of the Bascule/AMC (Amsterdam), and from PsyQ mental
health facility in The Hague. The diagnosis is made by an
experienced psychiatrist based on the Diagnostic and Statis-
tical Manual of Mental Disorders, (DSM-IV), Fourth
Edition, [14] and confirmed by a structured interview: Diag-
nostic Interview Schedule for Children (National Institute
of Mental Health Diagnostic Interview Schedule for Chil-
dren Version IV (NIMH-DISC-IV, authorized Dutch Trans-
lation) [15], in children or in parents and the Diagnostic
Interview for Adult ADHD (DIVA) [16] in adults in the
RCT with MPH. For the ePOD-SSRI trial we use the Diag-
nostic Interview Schedule for Children in children and in
adults the Composite International Diagnostic Interview
(CIDI; lifetime version 2.1 authorized Dutch translation)
[17]. In addition, children must have a Children’s Depres-
sion Rating scale-Revised (CDRS-R) [18] score of > 45, and
a Children’s Global Assessment Scale (CGAS) [19] score <
50. In adults, a Hamilton Rating Scale for Depression
(HRSD-17) [20] ≥18, a Clinical Global Impression scale
(CGI) [21] > 4, and or Hamilton anxiety scale (HAM-A) >
20 [22] are required for study inclusion. Subjects must ex-
hibit stable dysphoria/depressed mood and/or anhedonia
for at least 2 weeks prior to enrollment and mood should
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two of three contexts: at home, at school or with friends).
In both RCTS, patients with co-morbid axis I psychiatric
disorders requiring treatment with medication at study
entry, with IQ lower than 80 (as measured by a subtest
of the Wechsler Intelligence Scale for children-Revised
(WISC-R), National Adult Reading Test (NART), autho-
rized Dutch translation [23] and MDD patients with
current risk of suicide attempt are excluded.
We chose to include only male patients in ePOD-MPH
to limit subject variation and because ADHD is most
prevalent in males [24]. Thus, to keep our sample as
homogenously as possible and prevent inclusion prob-
lems, only male subjects are included in the ePOD-MPH
study. The cut-off point of 10–12 years of age was chosen
because peak prevalence of ADHD is 10 years of age [25]
and also because several MRI parameters greatly change
until 8–10 years of age [26], whereas the rate of increase
of neuronal growth and pruning reduces after 10 years of
age. The cut off point of 23 years for matured brain in the
adults is chosen in line with previous studies involving a
comparison between matured versus immature brain [27].
Only female subjects are included in ePOD-SSRI based
on the higher prevalence of MDD and AD in this popula-
tion [28]. Thus, to keep our sample as homogenously as
possible and prevent inclusion problems, only female sub-
jects are included in the ePOD-SSRI study. For the adoles-
cent group we chose a cut-off point of 12–14 years of age
because the risk of MDD and AD onset increases approxi-
mately 8 fold at this age compared to children younger than
10 years of age [29,30].
Cohort based study: design and study sample
In the ePOD-Pharmo study, we investigate the long-term
effects of age following SSRI or MPH treatment on our
main outcome parameter (phMRI). Exposed subjects are
stratified into two age groups: one group that has been pre-
scribed early in life with these medications, and another
group late in life. Subjects are recruited through a medical
prescription database from the Pharmo Institute (Utrecht,
the Netherlands). This out-patient pharmacy database is a
database that contains drug dispensing data since 1986
from over 3 million residents in the Netherlands, corre-
sponding to approximately 20% of the Dutch population.
The dispensing date, prescriber, prescribed dosage regimen,
and duration are known. Subjects participate in a single as-
sessment day (cross-sectional design) with similar NPA
and MRI investigations as in the ePOD RCTs, mentioned
above. Subjects eligible for study participation are 23–
40 years of age and presumably diagnosed with ADHD or
MDD/anxiety disorder. The early exposed group contains
subjects with a history of MPH (male subjects) or SSRI
treatment (female subjects) before the age of 16 (thus at
least 7 years ago). The late exposed group contains subjectstreated between 23 and 40 years of age. The early-, and late
exposed groups will be compared to an age-, and gender
matched unexposed control group, consisting of medica-
tion naive subjects suffering from ADHD or MDD/anxiety
disorder. Every group (six in total) will contain 25 subjects.
Assessments
Clinical rating scales
For both RCTs we use a set of clinical rating scales to assess
symptom severity and functioning at baseline and after
treatment. For each study separately we have some add-
itional, disorder-specific rating scales. In the ePOD-MPH
RCT, an authorized Dutch translation of the Disruptive Be-
havior Disorders Rating Scale (DBD-RS) [31] will be used
in children and in adults the ADHD-SR [32]. Clinical im-
provement will be rated in both RCTs by the clinician using
CGAS [19] and CGI [21] scales in children, and in adults
using the Global Assessment of Function [33]. In both
RCTs, the Children’s Depression Inventory (CDI) [34] and
the Screen for Child Anxiety Related Emotional Disorders
(SCARED) [35] will be administered to children, and the
Beck Depression Inventory (BDI) [36] and the Beck Anxiety
Index (BAI) [37] to adults. These rating scales are also ad-
ministered in the ePOD-Pharmo study.
Imaging parameters
Imaging parameters are directed towards the DAergic and
5-HTergic system. DAergic and 5-HTergic brain activity
will be assessed using phMRI, which is the primary out-
come measure of the ePOD project. In addition, DA con-
nectivity will be assessed using rs-fMRI and DTI, and
functional brain activity using DA-related (motor inhib-
ition) or 5-HT-related (emotional processing) fMRI tasks.
Due to time restrictions of the ePOD-SSRI scan protocol,
5-HT connectivity will only be assessed using DTI.
phMRI
Application of fMRI in combination with a pharmaco-
logical challenge (phMRI) has the potential to provide
an index of changes in neurotransmitter function. With
phMRI a neurotransmitter specific pharmacological chal-
lenge is given, which causes changes in neurovascular
coupling and subsequent region-specific changes in brain
hemodynamics. It differs from fMRI, in that the neuronal
system is not activated by a motor or cognitive task, but
pharmacologically. phMRI has been shown to adequately
assess the DA integrity and functionality, as DA-lesioned
primates showed a blunted hemodynamic response to a d-
amphetamine challenge, following DA lesioning, which
correlated strongly with DA transporter availability and
motor function [38]. During the phMRI scan, after several
minutes of baseline scanning, subjects will receive an oral
dose of MPH (0.5 mg/kg with a maximum dose of 20 mg
in children and 40 mg in adults). This challenge dose was
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occupancy), which occurs at serum concentrations of
about 8–10 ng/ml. Higher concentrations are not likely to
be very effective in further blocking DAT [39]. After 90 mi-
nutes, subjects will undergo a second MRI session, and
the same MRI sequences are repeated, now under the in-
fluence of MPH. The 90 minute time window was chosen,
because DAT occupancy is significantly correlated with
plasma concentration of MPH, which peaks between 1
and 2 hours following ingestion of MPH [40,41]. DAT oc-
cupancy has also been shown to be relatively stable be-
tween 1 and 2 hours after ingestion of MPH [40]. Based
on the literature (reduction in DAT densities in young,
but not adult treated animals) [42] and experiments from
our own group in d-amphetamine users with phMRI and
a MPH challenge [43], we expect that treatment with
MPH will induce a long-lasting changes in the brain
hemodynamic phMRI response in DA rich brain areas (e.
g. striatum) in children, but not adults. We expect that in
adult patients MPH will be accommodated by a series of
transient compensatory reactions. However, in children
MPH will induce changes in the form of long-lasting de-
velopmental alterations of the system, reflecting existence
of ‘neuronal imprinting’ in the human brain [44].
In the ePOD-SSRI study, an intravenous (i.v.) challenge
with citalopram (5 mg in adolescents and 7.5 mg in adults)
will be administered during a single scanning session. A 5-
HT challenge is subject to more variability and therefore
needs to enter the brain in a rapid and consistent manner
over the time course of a single scan session, which re-
quires intravenous administration [45]. Citalopram is cur-
rently the only SSRI registered for i.v. administration.
When used for therapeutic purposes, intravenous citalo-
pram is given at the same dose as the oral route of admin-
istration and it is well within the therapeutic range even
for children [46]. Citalopram increases 5-HT release by
inhibiting the reuptake of 5-HT by SERT. It has been used
previously in phMRI studies and has been proven an ad-
equate probe of 5-HT function [45,47]. We have previ-
ously shown that phMRI is able to detect 5-HT neuronal
imprinting effects: in young rats chronic FLX treatment
resulted in an increased 5-HT reactivity as measured with
phMRI, whereas in adult animals FLX it reduced 5-HT
brain activity [48]. We expect an increased signal in 5-HT
rich brain areas (e.g. prefrontal cortex, hippocampus and
hypothalamus) after 5-HT challenge only in FLX treated
adolescents when compared to pretreatment baseline
scans, in line with our previous findings in rats [48].
rs-fMRI
A relatively new fMRI approach (i.e., resting-state fMRI
(rs-fMRI)) allows assessment of changes in organization of
whole functional networks, including DAergic and 5-
HTergic networks. Rs-fMRI detects baseline brain activityrelated to ongoing neuronal signaling at “rest” and is
performed by low-pass filtering of spontaneous blood
oxygenation level-dependent (BOLD) fMRI signals [49].
A decreased functional connectivity between anterior
cingulated cortex and precuneus has been found using
this technique in adult ADHD patients [50]. There are a
number of studies that have investigated the effects of
MPH or SSRIs on this parameter [14,51-55], which
found that these drugs normalize brain activation and
functional connectivity abnormalities in patients suffer-
ing from ADHD or MDD. In accordance with this lit-
erature, we expect to find age-dependent normalization
of functional connectivity abnormalities.DTI
With diffusion tensor imaging (DTI), the micro-
structural organization of white matter (WM) can be
visualized. By measuring the diffusion motion of water
molecules, and the fact that this motion is restricted by
myelin sheaths, an impression of axonal direction and
integrity can be obtained [56]. Fractional anisotropy
(FA) is the most commonly used readout marker in
DTI and provides information about the degree of fiber
organization and integrity. Any process that results in
alterations in axonal architecture, such as decreased
axonal outgrowth, can result in decrease in FA [57-59].
A previous DTI study in children suffering from
ADHD, observed an increase, or rather normalization,
of white matter volume in ADHD medicated children
compared to unmedicated children [60]. In line with
this, chronic treatment with MPH in pre-adolescent
rats was found to increase (fold change >1.5) genes in-
volved in striatal growth of novel axons [61]. Further-
more, in a recent study in rats we observed opposite
effects of MPH on FA measures: MPH induced an
increase in FA in the corpus callosum of adolescent rats,
whereas a slight reduction in adult animals [62]. There-
fore, we also expect to find age-related findings in the
current RCT with MPH: an increase in FA in MPH
treated children when compared to pre-treatment baseline
scans, and no effect or a small effect in adult patients.
Considering the 5-HTergic system, we have previ-
ously shown that alterations in axonal integrity linked
to the 5-HTergic system can be adequately assessed
using DTI [59]. We hypothesize that chronic treatment
with SSRIs leads to increased outgrowth of the 5-HT
system, since 5-HT acts as a growth factor in the ma-
turing brain [63]. Therefore we expect an increase in
FA (reflecting 5-HT neuronal growth) in 5-HT rich
brain areas only in FLX treated adolescents when com-
pared to pretreatment baseline scans. Like for MPH,
no effect of treatment on these scan parameters are ex-
pected in adults.
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We have selected two task-related fMRI scans either
based upon their involvement of the DA system and/or
the 5-HT system and the known interaction with MPH
or FLX and treatment response in anxiety and depressive
disorders. In view of our hypothesis we expect to find a
normalized pattern of activation on these tasks in chil-
dren during treatment, which will persist after the end
of the trial. In contrast, the activation pattern in adult
subjects will normalize during the trial and fall back to
pre-treatment (hypoactivation) values after the end of
the trial. The fMRI tasks consist of the following:
An emotional processing task (MPH and SSRI trials,
and ePOD-Pharmo study): The BOLD response to nega-
tive emotional faces (angry and fearful faces) is measured
in a block-design fMRI task [64]. Emotional responses are
elicited in many different brain regions, where the amyg-
dala seems to be a relay between visual systems en modu-
latory responses. Emotional processing is known to be
regulated by 5-HT and to be affected in mood disorder
[65]. MDD patients are believed to express a heightened
responsiveness to negative emotional stimuli and a re-
duced detection of positive affect [66,67], which is ex-
plained by hyperactivity of the affective neurocircuitry,
including the amygdala [68]. SSRIs have been found to de-
crease amygdala activity in response to negative affect in
both healthy subjects and MDD patients, which might
(partially) explain symptom remission following anti-
depressant treatment in MDD [69-71].
A motor inhibition task (only MPH trial and ePOD-
Pharmo study): Frontal–striatal function and its modulation
by MPH will be assessed using a motor inhibition task: the
go/no-go task [72]. MPH has been shown to normalize stri-
atal hypoactivation in ADHD subjects [73]. Specifically,
fronto–striatal activation during response inhibition will be
measured on two versions of a go/no-go task, each with
and without administration of MPH. The effects of MPH
on frontal and striatal activation during response inhibition
will be compared within and between groups.
Neuropsychological tests
A neuropsychological test battery (Standard Reaction
Time Task, Rey Auditory Verbal Learning Task [74], Sus-
tained Attention to Response Task (SART) [75], N-back
(working memory task) [76], Maudsley Index of Delay
Aversion (MIDA) [77]) will be administered, addressing
reaction time, verbal memory, sustained attention, work-
ing memory and delay aversion in particular. This infor-
mation can be linked to results from imaging in order to
determine any links between behavioral and fMRI data
and changes in the monoamine systems. We will look for
correlations between altered cognitive responses and fMRI
responses, phMRI responses, DTI measures and rs-fMRI
response.Actigraphy and sleep log
Restless Legs Syndrome is a chronic progressive neuro-
logical disorder that has a greater incidence in ADHD chil-
dren, adolescents and adults than in the general population
[78]. It is possible that RLS is co-morbid with ADHD or
that they share a common DAergic deficit. Also, ADHD
separately and ADHD together with RLS have been found
to be associated with sleep disorders such as insomnia and
a common genetic polymorphism [79-81]. In a recent
study, 64% of children with ADHD were estimated to suffer
from RLS judged by their nocturnal periodic limb move-
ment [82]. It has been shown that MPH reduces total sleep
time but improves sleep quality by consolidating sleep in
adults [83]. However, the effect of MPH on RLS in ADHD
children has never been investigated. In view of the ex-
pected inhibitory effect of MPH on DA metabolism it is
important to investigate the occurrence and severity of RLS
and sleep disorders in children and compare these to
adults, and the effect of MPH thereupon. Sleep disorders
and RLS are effective and non-invasive outcome measures
to evaluate the effect of age following MPH treatment in
the human brain. Therefore, we will assess RLS severity
and sleep quality in the ePOD-MPH trial using question-
naires (Cambridge-Hopkins RLS questionnaire(CH-RLSq,
International RLS severity scale (iRLSS), John Hopkins RLS
severity scale (JH-RLS-ss), Epworth sleepiness scale (ESS)
and the the Holland Sleep Diagnostic List (HSDL)) [84]
and sleep log and actigraphy at three time points during
the study: the week prior to the trial, during the trial, and
during the washout period. Actigraphy is a non-invasive
method of monitoring human rest/activity cycles. To
measure gross motor activity, each patient will wear a
small actigraph unit, also called an actimetry sensor, for
five consecutive days. We hypothesize that due to an ex-
pected long-term reduction in DA turnover rate after early
MPH treatment, there will be long lasting positive effects
on RLS symptoms and sleep disorders only in children,
but not adults.
Cortisol measurements
In the ePOD-SSRI study salivary cortisol levels will be
determined in salivary samples taken at home on a ‘nor-
mal’ weekday in the week before baseline and washout
assessment days in order to determine the cortical awak-
enings response (CAR) and the diurnal cortisol cycle.
Samples will be collected at 5 different moments: 1) dir-
ectly after waking up, 2) 30 minutes after waking up, 3)
4 hours after waking up, 4) 8 hours after waking up,
and 5) and 12 hours after waking up. To determine the
peak after a 5-HT challenge, one salivary sample will be
collected before the MRI scan session (baseline measure)
and a second sample 30 minutes after the 5-HT chal-
lenge (directly after the MRI scan) on the day of both
the MRI scan sessions.
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The study is designed to limit several important possible
confounding parameters, such as gender effects (only
women are included in the FLX trial and only men in
the MPH trial) and aging effect (small age range, only
young adults included). A within subject approach (pre-
and post-treatment measurement in every subject) is used
to rule out most between subject differences in the RCTs.
Because of the design of the study, we have limited power
and can correct for a maximum of 2 or 3 confounders.
Therefore, age (in months) and ratings of symptom sever-
ity will be taken into account as covariates. In addition in
the ePOD-SSRI study, the 5-HTTLPR polymorphism will
be determined. The long allele of this SERT polymorphism
in the promoter region (5-HTTLPR) has an activity twice
that of the short allele [85], resulting in higher densities of
SERT. It is expected to be an important confounder to
take into account when measuring SERT functioning.
Also, significant associations between the long variant and
a favorable treatment response have been repeatedly re-
ported [86].Power analysis
Since these trials are the first to examine 5-HT and DA
functioning following FLX and MPH treatment in chil-
dren and young adults using MR imaging, there is only
limited and indirect data available to perform a sample
size calculation. The goal of our research is to detect dif-
ferences in the age-dependency effect of FLX and MPH
on the outgrowth of the DA-ergic and 5-HT-ergic system
if these differences are in the magnitude of a standardized
effect size of 1.25. From pilot experiments in rats and
studies in humans with known alterations of 5-HT and/or
DA (e.g., MDMA users or d-amphetamine users) we pre-
sume that the expected differences with our methods will
lead to standardized effect sizes of at least 1.25. Both
current trials will have the benefit of having before and
after treatment measurements data from each patient.
This paired data will reduce the between subject variabil-
ity. This will increase the power of our trial to detect dif-
ferences between groups. A sample size of 15 patients in
each treatment-by-age group (4 groups) will be sufficient
to detect standardized effect size of 1.25 with a two-sided
significance level of 5% and a power of 90% to demon-
strate age-dependency of the effects of MPH and FLX. To
account for an expected drop-out of 25%, we will include
20 patients in each group for the FLX trial. Because the
expected drop-out in the MPH trial is probably higher,
due to motion artifacts in MRI scanning, we will include
25 patients in each treatment-by-age group. Because of
slightly higher subject variability in the ePOD-Pharmo
study (age and duration of treatment) again a sample size
of 25 was chosen.Statistical analysis
To evaluate the age-dependency of the effect of MPH and
FLX on the outgrowth of the DA-ergic and 5-HT-ergic sys-
tem, the change in our primary outcome measures (CBF)
from baseline to post-treatment will be determined for each
patient (Δi). These individual changes (Δi) will be used to
estimate the treatment effect in adolescents (mean Δ in
treated patients minus mean Δ in placebo treated patients)
and in adults, which will be compared, as shown also in
Figure 2. All analysis will initially be conducted using the
intension-to-treat principle, but for the imaging outcomes a
per-protocol analysis will also be performed.
The central analysis examines whether this treatment ef-
fect is different in adolescents compared to adults (effect
modification or interaction by age). This hypothesis will
be formally examined using ANOVA. The model includes
treatment group (2 categories), age group (2 categories),
and the interaction between treatment and age to examine
whether the impact of MPH and FLX treatment differs by
age. Depending on the imaging modality we will use a
whole brain voxel based analysis or an ROI analysis. The
same approach can be used for explorative analysis on the
age-dependency of the effects on secondary outcome mea-
sures such as behavioral outcome (fMRI, neuropsycho-
logical assessment) and behavioral measures, and cortisol
response for the FLX trial and sleep-log actigraph for the
MPH trial.
Ethical considerations
Evidently, there are important ethical considerations that
need to be taken into account with medication studies
in children. In our case, the most important restriction
is the duration of the clinical trial, or the time that a
child would not receive adequate treatment (placebo
condition). The duration of the RCT could not be longer
than the time a child would otherwise also not receive
adequate treatment, due to (relatively) long waiting lists
in the Netherlands: typically 4 months at the time these
studies were being evaluated by the Central Committee
on Human Research in the Netherlands (CCMO). In the
MPH study we overcome the treatment delay by including
patients from the waiting list and offering psycho-education
when necessary. In addition, in the ePOD-SSRI trial we give
at least 18 sessions Cognitive Behavioral Therapy (CBT) to
all adolescent participants. Therapy will be in accordance
with the ‘Doepressie’ protocol, a psychotherapeutic pro-
gram which is a Dutch translation of the internationally
well-used program ‘Coping with Depression Course for
Adolescents’ [87]. CBT is not part of standard clinical prac-
tice in the adult MDD population and will therefore not be
provided to the adult patients. Adult MDD patients, who
already receive some form of behavioral therapy at the start
of the study, may continue this if they wish, but adult MDD
patients cannot start a new therapy. Moreover, studies with
Figure 2 ‘Comparison of mean Δ in treated patients minus mean Δ in placebo treated patients’.
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sponse up to 40% making treatment with placebo more
ethically acceptable.
The RCTs have been approved by the Central Commit-
tee on Human Research in the Netherlands (CCMO), the
Pharmo cohort study has been approved by the local med-
ical ethics committee (METC) of the Academic Medical
Center Amsterdam (AMC). All subjects participate on a
voluntary base and receive a small financial compensation
(50 euro and travel expenses). Written and informed con-
sent from both patients and legal caregivers will be ob-
tained in all cases.
Discussion
In the ePOD project we propose a set of neuroimaging
studies and neuropsychological assessments in which we
examine the neural circuitry in adolescents with depression
or anxiety and ADHD before and after treatment. As
pointed out recently in an editorial from the American
Journal of Psychiatry [88], this type of research is greatly
needed in a field in which most imaging studies have been
conducted in adults. Because of ongoing brain develop-
ment during adolescence, the neuropathophysiology, let
alone the treatment, that underlie these disorders could be
distinct. Slowly emerging evidence suggests that the long-
term effects of drug exposure are delayed and expressed
once the vulnerable system reaches maturation (i.e., typic-
ally during adulthood). This phenomenon, known as neur-
onal imprinting, occurs when the effects of drug exposure
outlast the drug itself [44]. Thus, understanding the per-
sistent effects critically depends on the window of observa-
tion. Therefore, ePOD is a unique clinical study in children
and adults which will exactly grab this window of oppor-
tunity to measure age related effects of psychotropic drugs
with sophisticated neuroimaging techniques. Embracingthis concept should influence how we conduct preclinical
assessments of developmental drug exposure, and ultim-
ately how we conduct clinical assessments of drug efficacy,
effectiveness, and safety for the treatment of childhood
psychiatric disorders [12].
As the safety of antidepressants to children still is a sub-
ject of concern, particularly since FLX is now licensed for
the treatment of MDD in children of 8 years and older, in-
formation about the safety of FLX in treating childhood
depression is needed. Especially the potential for an in-
creased suicide risk in association with SSRIs in general
has led to much debate [89], as has also been pointed out
by the Medicines Evaluation Board of the Netherlands
[90] and several comments in the Lancet in response to an
article by Ebmeier and colleagues [91].
The neurotransmitter 5-HT plays a crucial role in
axonal outgrowth of 5-HT projections during brain devel-
opment [63]. Earlier animal work demonstrated that post-
natal 5-HT pharmacological manipulations can lead to
abnormal outgrowth of the 5-HT system [92-94]. As an
SSRI, FLX increases extracellular 5-HT concentrations by
blocking SERT. Recently, studies in non-human primates
have shown that FLX persistently upregulates SERT, but
not 5-HT1A receptors, in the neocortex and the hippo-
campus of non-human primates [7]. These findings are in
line with pilot experiments of our group and findings of
Wegerer et al. and Bock et al., in rats, which also indicated
that this effect persists into adulthood, long after discon-
tinuation of treatment with SSRIs [5,6]. Also, we showed
with phMRI that juvenile-treated rats respond more
strongly to a 5-HTchallenge than same-age untreated rats,
while adult-treated rats show a diminished response after
previous chronic treatment [48]. This study showed that
the phMRI technique is very well suited to address the pri-
mary objective of the ePOD-MPH studies: investigating
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age. As may be expected, on a behavioural level, results
are less consistent, although age-dependent responses to
SSRIs on depression-like behaviour are described in both
rats and mice [2,95,96]. All these findings most likely re-
flect the earlier described neuronal imprinting effects.
MPH is being prescribed to increasingly younger chil-
dren [97,98]. A meta-analysis has shown that in the USA
and Australia up to 18 – 66% of those treated with stimu-
lants do not meet the criteria for ADHD [99]. The in-
creased prescription rates and concerns about proper
diagnostic protocols have led to much public debate on
the safety of MPH in the treatment of children. Indeed, a
meta-analysis has shown that non-compliance is estimated
at 20-65% and is attributed in part to apprehension about
the safety of psychostimulants [100]. Recent work on the
effects of MPH has shown that it may indeed normalize
rates of cortical thinning, especially that of the prefrontal
cortex [13]. In addition, in adult ADHD several reports on
grey matter reductions were not able to distinguish be-
tween ADHD and psychostimulant effects [101,102].
However, reports on greater rates of depression and anx-
iety in the treated groups of the MTA study sample and in
several studies involving rats indicate that effects of MPH
treatment may have mixed positive and negative effects
[9,10,103]. Our main outcome parameter phMRI may be
able to shed more light on the effects of MPH on the de-
velopment of the DAergic system. This will increase our
understanding of the safety and working mechanisms of
MPH in a vulnerable population. In addition, we will gain
insight into basal neurocognitive and neuroadaptive pro-
cesses in the developing brain, as well as increasing our
knowledge on the pathophysiology of ADHD.
However, there are also some limitations of the present
study designs that need to be mentioned. One limitation is
that the treatment provided to adolescents and adults is
not the same in the ePOD-SSRI RCT. Adolescent subjects
will receive CBT, whereas adult patients will not. As men-
tioned previously, CBT is not part of standard clinical
practice in the adult MDD population and will therefore
not be provided to the adult patients. From a methodo-
logical point of view it would have been ideal to isolate the
effect of FLX and add no other treatment than this one in
both age groups. However, this is not ethical as CBT is al-
ways part of standard clinical practice in the Netherlands
in adolescent patients suffering from MDD. However,
since change scores from baseline to post-treatment will
be determined for each patient (Δi), the potential effect of
(the lack) of CBT will be minimized. Another limitation is
that no conclusions from the ePOD-SSRI and ePOD-
MPH RCTs can be made on the long-term effects of these
medications on brain development. The RCTs last for
‘only’ 4 months, and the washout period is 3 weeks max-
imum. For that reason, we designed the ePOD-Pharmostudy, in which subjects are screened at least 7 years later
following early FLX or MPH exposure. In addition, all par-
ticipants in the RCTs are asked if they are willing to partici-
pate in a follow up study, scheduled in 3–5 years, and most
are willing to participate. Thus, by combining the RCTs in
which we investigate the causality of the age-dependency
of FLX and MPH, together with the ePOD-Pharmo study
which is directed towards the long-term effects of these
medicines, will ultimately provide missing knowledge.
As recently indicated by Tao and colleagues, studies
are needed that use the same methodology simultan-
eously in both adolescents and adults, to overcome
methodological differences, and correct interpretation
of the age-dependency of results [104]. Sample differences
in age and illness status or differences in the image acqui-
sition/analysis approach may obscure the age-dependency
of the findings. These issues are overcome by the current
study design. Since this study employs randomized con-
trolled trials and has the benefit of having before and after
treatment measurements from each patient, we will be
able to reduce subject variability. This increases the ability
of our trial to detect differences between groups. More-
over, this study employs novel non-invasive MRI tech-
niques in children and adolescents, which provide new
insights into the effects of psychotropic drugs on the de-
veloping brain. The use of phMRI in assessing DAergic
and 5-HTergic functionality may have important prognos-
tic factors, for instance in predicting responsiveness to
psychostimulants or antidepressant medication in the near
future.
Conclusion
So far, most imaging studies have been conducted in
adults. Ongoing brain development during adolescence
may distinct the neural mechanisms that underlie psychi-
atric disorders like depression, anxiety and ADHD. Exam-
ination of these mechanisms during early phases of the
disorder provides the opportunity to avoid confounds due
to complex treatment histories or potential scarring from
years of disease. A better understanding of adolescent-
specific mechanisms will be “a critical foundation for the
advancement of early treatment interventions, which could
significantly affect public health” [88].
In the ePOD studies we propose a set of neuroimaging
studies and neuropsychological assessments in which we
examine the neural circuitry in adolescents with depres-
sion or anxiety and adolescents with ADHD before and
after treatment. The combination of prospective studies
with a cross-sectional cohort study, using the same out-
come measures, will increase our understanding not
only of the working mechanisms of both FLX and MPH
in children and adolescents, but also provide more infor-
mation about the safety of these substances in the ma-
turing brain.
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